{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T19:20:26Z","timestamp":1788636026306,"version":"build-2803163510"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T00:00:00Z","timestamp":1570233600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T00:00:00Z","timestamp":1570233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Guangzhou Science and Technology Project","award":["grant 201804010477"],"award-info":[{"award-number":["grant 201804010477"]}]},{"name":"National Health and Family Control Committee","award":["grant 201402031"],"award-info":[{"award-number":["grant 201402031"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10147-019-01552-5","type":"journal-article","created":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T17:08:37Z","timestamp":1570295317000},"page":"267-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Retrospective study on bevacizumab in the treatment of non-small cell lung cancer with brain metastases"],"prefix":"10.1007","volume":"25","author":[{"given":"Zhen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ji","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Yan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Hong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Long","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,5]]},"reference":[{"issue":"2","key":"1552_CR1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115\u2013132. \nhttps:\/\/doi.org\/10.3322\/caac.21338","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1552_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7\u201330. \nhttps:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1552_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2213-2600(17)30262-X","volume":"5","author":"JJ Yang","year":"2017","unstructured":"Yang JJ, Zhou C, Huang Y et al (2017) Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial. Lancet Respir Med 5(9):707\u2013716. \nhttps:\/\/doi.org\/10.1016\/S2213-2600(17)30262-X","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1552_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1093\/annonc\/mds590","volume":"24","author":"JC Soria","year":"2013","unstructured":"Soria JC, Mauguen A, Reck M et al (2013) Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24(1):20\u201330. \nhttps:\/\/doi.org\/10.1093\/annonc\/mds590","journal-title":"Ann Oncol"},{"issue":"19","key":"1552_CR5","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1200\/JCO.2014.59.4424","volume":"33","author":"C Zhou","year":"2015","unstructured":"Zhou C, Wu YL, Chen G et al (2015) BEYOND: a randomized, double-blind, placebo-controlled, multicenter, phase III study of first-line carboplatin\/paclitaxel plus bevacizumab or placebo in chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer. J Clin Oncol 33(19):2197\u20132204. \nhttps:\/\/doi.org\/10.1200\/JCO.2014.59.4424","journal-title":"J Clin Oncol"},{"issue":"8","key":"1552_CR6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","volume":"11","author":"L Crino","year":"2010","unstructured":"Crino L, Dansin E, Garrido P et al (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 11(8):733\u2013740. \nhttps:\/\/doi.org\/10.1016\/S1470-2045(10)70151-0","journal-title":"Lancet Oncol"},{"issue":"8","key":"1552_CR7","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1078-0432.CCR-14-2082","volume":"21","author":"B Besse","year":"2015","unstructured":"Besse B, Le Moulec S, Mazieres J et al (2015) Bevacizumab in patients with nonsquamous non-small cell lung cancer and asymptomatic, untreated brain metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res 21(8):1896\u20131903. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2082","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1552_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1200\/JCO.2001.19.3.843","volume":"19","author":"MS Gordon","year":"2001","unstructured":"Gordon MS, Margolin K, Talpaz M et al (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19(3):843\u2013850. \nhttps:\/\/doi.org\/10.1200\/JCO.2001.19.3.843","journal-title":"J Clin Oncol"},{"issue":"1","key":"1552_CR9","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1158\/1078-0432.CCR-09-2439","volume":"16","author":"B Besse","year":"2010","unstructured":"Besse B, Lasserre SF, Compton P et al (2010) Bevacizumab safety in patients with central nervous system metastases. Clin Cancer Res 16(1):269\u2013278. \nhttps:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2439","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1552_CR10","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.lungcan.2011.11.020","volume":"76","author":"E Dansin","year":"2012","unstructured":"Dansin E, Cinieri S, Garrido P et al (2012) MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer 76(3):373\u2013379. \nhttps:\/\/doi.org\/10.1016\/j.lungcan.2011.11.020","journal-title":"Lung Cancer"},{"issue":"2","key":"1552_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. \nhttps:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"24","key":"1552_CR12","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa061884","volume":"355","author":"A Sandler","year":"2006","unstructured":"Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542\u20132550. \nhttps:\/\/doi.org\/10.1056\/NEJMoa061884","journal-title":"N Engl J Med"},{"issue":"12","key":"1552_CR13","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1111\/cas.13096","volume":"107","author":"K Goto","year":"2016","unstructured":"Goto K, Endo M, Kusumoto M et al (2016) Bevacizumab for non-small-cell lung cancer: a nested case control study of risk factors for hemoptysis. Cancer Sci 107(12):1837\u20131842. \nhttps:\/\/doi.org\/10.1111\/cas.13096","journal-title":"Cancer Sci"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01552-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01552-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T23:22:28Z","timestamp":1601767348000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01552-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,5]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1552"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01552-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,5]]},"assertion":[{"value":"6 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The trial was approved by Guangdong Provincial People\u2019s Hospital ethics committees and complied with the Declaration of Helsinki and Good Clinical Practice principles.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}